Bitwise is preparing to debut its spot Solana Staking ETF (exchange-traded fund) on the New York Stock Exchange (NYSE) today with Canary Capital set to [...]Bitwise is preparing to debut its spot Solana Staking ETF (exchange-traded fund) on the New York Stock Exchange (NYSE) today with Canary Capital set to [...]

Kalshi Sues New York Regulator Over Move To Block Its Sports Betting Contracts

2025/10/28 18:00
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Prediction market Kalshi has filed a federal lawsuit against the New York State Gaming Commission after the regulator ordered it to stop offering contracts tied to sports outcomes.

In a complaint filed in a Manhattan federal court, Kalshi said the state regulator had no authority over its operations because it is a registered exchange with the US Commodity Futures Trading Commission (CFTC).

The firm argued that its event contracts, including those linked to sports results, are federally regulated derivatives rather than wagers.

The lawsuit followed a cease-and-desist letter from the New York regulator on Friday accusing Kalshi of facilitating unlicensed sports wagering and threatening it with “imminent civil penalties and fines.”

It requested a preliminary and permanent injunction from the court, as well as a court declaration stating that the New York regulator can’t regulate the platform under the Constitution.

Kalshi Says State’s Action Would Expose It To ‘Patchwork Of Regulations’

It also said the state’s actions threaten to subject Kalshi to the patchwork of state regulation that Congress created the CFTC to prevent.

Kalshi is currently registered as a designated contract market (DCM) with the CFTC. This gives the platform the federal right to list and clear derivatives that are tied to real-world events, which may include sports outcomes, the company said in its filing.

Kalshi offers multiple sports-events contracts, which allow users to bet on whether a team will win or advance in a tournament. Users can also bet on other spots outcomes on the platform. 

The company had self-certified those sports contracts with the CFTC earlier this year. 

Kalshi Says It’s Only Subject To The CFTC’s Jurisdiction

Kalshi argued that it is “subject to the CFTC’s exclusive jurisdiction” under the federal Commodity Exchange Act and said the state’s actions could lead to “immediate and irreparable harm.”

Kalshi added that it’s trapped between a rock and a hard place. If it chooses not to comply, it faces civil and criminal liability, but if it does it will “incur substantial economic and reputational harm.” 

Kalshi sports betting (Source: Kalshi)

Not Kalshi’s First Legal Battle With State Regulators

Kalshi has also sued state gambling regulators in Nevada, Ohio, Maryland, and New Jersey over similar circumstances. Kalshi is also defending itself against allegations made by Massachusetts for allegedly violating its sport betting laws.

Kalshi has won preliminary injunctions in the New Jersey and Nevada federal courts, victories it said helped prevent “similar state overreach.” 

But a Nevada federal judge said in April that Kalshi would likely not suffer harm if the court did not block the state’s gaming regulator. A similar conclusion was reached by a New Jersey federal judge a month later, while a federal court in Maryland denied Kalshi’s request to block the state’s regulator in August.

Other platforms that offer event contracts, such as Crypto.com and Robinhood Markets, have also filed legal actions to defend themselves from state regulators. 

Market Opportunity
Movement Logo
Movement Price(MOVE)
$0.02126
$0.02126$0.02126
-0.74%
USD
Movement (MOVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09